Trial Master File (TMF)

The Trial Master File (TMF) is the master record of a clinical trial’s conduct: the organized collection of essential documents — protocol, approvals, consent forms, monitoring reports, and more — that lets a sponsor, auditor, or regulatory inspector reconstruct and evaluate how the trial was actually run and whether its data can be trusted. ICH GCP, specifically ICH E6(R2) Section 8, is the primary source defining what belongs in it.

What ICH E6(R2) Requires

ICH E6(R2) Section 8 defines essential documents as those which “individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced.” It groups them into three sections by when they are normally generated:

• Before the clinical phase begins — the signed protocol and amendments, investigator’s brochure, informed consent form template, IRB/IEC approval, financial agreements, and insurance/indemnity documentation.
• During the clinical conduct of the trial — protocol amendments, updated investigator’s brochures, signed informed consent forms, monitoring visit reports, correspondence, CRA site-visit logs, drug or device accountability records, and adverse event/safety reports.
• After completion or termination of the trial — the final clinical study report, subject identification code lists, audit certificates, and documentation of final accountability and disposition of investigational product.

Collectively, these are the same documents a sponsor’s independent quality/audit function reviews internally and that a regulatory authority inspects to confirm the validity of trial conduct and the integrity of the data collected — which is why inspection readiness is, in practice, largely a question of TMF completeness and currency.

Sponsor TMF vs. Investigator Site File (ISF)

The TMF has two parallel halves. The sponsor’s TMF (or the TMF maintained by a delegated Contract Research Organization) is the central, trial-wide record — covering the full protocol history, regulatory submissions, and every site’s approvals. Each participating site independently maintains an Investigator Site File (ISF): the site-level mirror covering the same essential-document categories as they apply locally — delegation-of-authority logs, that site’s IRB correspondence (see also the IRB/REC approval process guide), signed informed consent forms, and site drug/device accountability. Neither file substitutes for the other; a complete trial record requires both, and a regulatory inspection of a specific site will typically start with that site’s ISF, not the sponsor’s central TMF.

eTMF and the TMF Reference Model

Paper TMFs (banker’s boxes of binders) are now largely legacy practice. Most sponsors, CROs, and larger sites maintain an electronic Trial Master File (eTMF) — a purpose-built or module of a broader Clinical Trial Management System (CTMS) that stores, version-controls, and tracks the completeness status of every required document, often with automated alerts for missing or expiring artifacts.

Rather than each organization inventing its own folder taxonomy, most eTMFs are structured around the industry-developed TMF Reference Model — originally a Drug Information Association (DIA) initiative and now maintained under CDISC — which organizes TMF content into roughly a dozen functional zones (e.g., Trial Management, Central Trial Documents, Regulatory, Investigational Product, Safety Reporting, Site Management), each broken down into sections and individual artifacts with defined metadata. Using a shared reference structure makes a TMF portable across CROs and vendor eTMF platforms and makes completeness auditable against a known artifact list rather than an informal checklist. [Industry-reported detail on the TMF Reference Model’s exact zone count and current version was corroborated across secondary sources — treat the precise version number as approximate if cited elsewhere, and verify against the current CDISC/DIA TMF Reference Model release before treating a specific version number as load-bearing.]

Why Regulators Care: TMF Quality as Inspection Evidence

A TMF is not paperwork for its own sake. FDA, EMA, and other regulatory authorities treat TMF completeness and quality as direct evidence of GCP compliance: a TMF that is incomplete, contains undated or unsigned documents, or cannot demonstrate that oversight activities (like monitoring) actually happened as documented is itself an inspection finding, independent of whatever the underlying trial data shows. This is the practical link between inspection readiness and good documentation practice in clinical trials more broadly — a TMF built and maintained to be inspection-ready throughout the trial, rather than assembled retroactively before an inspection, is both a compliance expectation and, in practice, far less work.

Related Terms

• Inspection Readiness
• ICH GCP (Good Clinical Practice)
• ICH E6(R2)
• IRB (Institutional Review Board)
• Informed Consent
• Clinical Trial Management System (CTMS)
• Good Documentation Practices (GDP) in Clinical Trials